批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2022/03/17 |
SUPPL-51(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/12/22 |
SUPPL-49(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2019/09/20 |
SUPPL-48(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/12/19 |
SUPPL-47(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/09/12 |
SUPPL-46(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2017/09/08 |
SUPPL-45(补充) |
Approval |
Labeling |
STANDARD
|
|
Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. |
2015/03/16 |
SUPPL-43(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2014/09/30 |
SUPPL-42(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/08/05 |
SUPPL-40(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2013/07/24 |
SUPPL-41(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/01/18 |
SUPPL-39(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2012/03/02 |
SUPPL-38(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/02/17 |
SUPPL-37(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/07/22 |
SUPPL-31(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2010/05/25 |
SUPPL-34(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2009/12/13 |
SUPPL-30(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2009/10/06 |
SUPPL-33(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2008/03/25 |
SUPPL-28(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2007/11/16 |
SUPPL-26(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2006/12/28 |
SUPPL-25(补充) |
Approval |
Manufacturing (CMC) |
N/A
|
|
|
2006/08/10 |
SUPPL-21(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2005/10/14 |
SUPPL-19(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2005/05/18 |
SUPPL-18(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2005/01/24 |
SUPPL-17(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2004/09/10 |
SUPPL-15(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2004/05/20 |
SUPPL-14(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2004/04/30 |
SUPPL-13(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/12/20 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2002/07/09 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2002/05/09 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2002/05/09 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2001/11/21 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:ERTAPENEM SODIUM 剂型/给药途径:INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 规格:EQ 1GM BASE/VIAL 治疗等效代码:AP
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
021337 |
001 |
NDA |
INVANZ |
ERTAPENEM SODIUM |
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS |
EQ 1GM BASE/VIAL |
Prescription |
Yes |
Yes |
AP |
2001/11/21
|
MSD SUB MERCK |
208790 |
001 |
ANDA |
ERTAPENEM SODIUM |
ERTAPENEM SODIUM |
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS |
EQ 1GM BASE/VIAL |
Prescription |
No |
No |
AP |
2018/04/16
|
ACS DOBFAR SPA |
209133 |
001 |
ANDA |
ERTAPENEM SODIUM |
ERTAPENEM SODIUM |
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS |
EQ 1GM BASE/VIAL |
Prescription |
No |
No |
AP |
2018/06/25
|
EUGIA PHARMA |
207647 |
001 |
ANDA |
ERTAPENEM SODIUM |
ERTAPENEM SODIUM |
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS |
EQ 1GM BASE/VIAL |
Prescription |
No |
No |
AP |
2019/03/19
|
SAVIOR LIFETEC CORP |
212040 |
001 |
ANDA |
ERTAPENEM SODIUM |
ERTAPENEM SODIUM |
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS |
EQ 1GM BASE/VIAL |
Prescription |
No |
No |
AP |
2021/03/26
|
GLAND PHARMA LTD |
209145 |
001 |
ANDA |
ERTAPENEM SODIUM |
ERTAPENEM SODIUM |
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS |
EQ 1GM BASE/VIAL |
Discontinued |
No |
No |
AP |
2023/05/02
|
SUN PHARM |
218067 |
001 |
ANDA |
ERTAPENEM SODIUM |
ERTAPENEM SODIUM |
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS |
EQ 1GM BASE/VIAL |
Prescription |
No |
No |
AP |
2024/10/31
|
QILU ANTIBIOTICS |